210 results on '"Schommers, Philipp"'
Search Results
2. Dynamics and durability of HIV-1 neutralization are determined by viral replication
3. Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals
4. MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study
5. Mapping the neutralizing specificity of human anti-HIV serum by deep mutational scanning
6. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope
7. Broadly neutralizing antibodies against HIV-1 and concepts for application
8. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
9. Semen enhances transmitted/founder HIV-1 infection and only marginally reduces antiviral activity of broadly neutralizing antibodies
10. Effective high-throughput isolation of fully human antibodies targeting infectious pathogens
11. Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections
12. Advancing bnAb combinations for HIV prevention
13. Kopf- und Halsinfektionen
14. Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV
15. 15-month post-COVID syndrome in outpatients: Attributes, risk factors, outcomes, and vaccination status - longitudinal, observational, case-control study
16. Antiretroviral treatment indications and adherence to the German-Austrian treatment initiation guidelines in the German ClinSurv HIV Cohort between 1999 and 2016
17. CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC)
18. Immunological fingerprint in coronavirus disease-19 convalescents with and without post-COVID syndrome
19. Metformin causes a futile intestinal–hepatic cycle which increases energy expenditure and slows down development of a type 2 diabetes-like state
20. 11 - Kopf- und Halsinfektionen
21. Mapping the neutralizing specificity of human anti-HIV serum by deep mutational scanning
22. Immune response to mRNA ‐based COVID ‐19 booster vaccination in people living with HIV
23. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns
24. A naturally arising broad and potent CD4-binding site antibody with low somatic mutation
25. Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens
26. Probabilities of HIV-1 bNAb development in healthy and chronically infected individuals
27. Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+ : CD8+ ratio
28. CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients
29. Delineating antibody escape from Omicron sublineages
30. Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study
31. Correction to: Antiretroviral treatment indications and adherence to the German-Austrian treatment initiation guidelines in the German ClinSurv HIV Cohort between 1999 and 2016
32. Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
33. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
34. CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients
35. Editorial: Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and Prevention
36. Do MYC Alterations Matter in HIV-Associated Large B Cell Lymphomas? the "Euromyc" Study (a European retrospective study)
37. Correction to: Treatment modifcation after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005–2017
38. CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma
39. Swarm Learning for decentralized and confidential clinical machine learning
40. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study
41. Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort
42. Restriction of HIV-1 Escape by a Novel Highly Broad and Potent Neutralizing Antibody
43. Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans
44. Characteristics and outcome of human immunodeficiency virus (HIV)‐associated primary effusion lymphoma as observed in the German HIV‐related lymphoma cohort study
45. 11 - Kopf- und Halsinfektionen
46. Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG
47. Recovered not restored: Long-term health consequences after mild COVID-19 in non-hospitalized patients
48. Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2
49. Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2
50. Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.